Cork based pharmaceutical technology company ArrayPatch has secured €3.2 million in funding to develop its dissolving patch delivery system for GLP-1 medications on 5 November 2026.
The company was founded by Dr Waleed Faisal, a formulation scientist who holds a PhD from University College Cork. ArrayPatch is developing innovative drug delivery technology that aims to replace traditional injection methods for administering GLP-1 receptor agonists, a class of medications commonly used for diabetes treatment and weight management.
Key facts
- ArrayPatch raised €3.2 million in investment funding
- The company is based in Cork, Ireland
- Dr Waleed Faisal, a University College Cork PhD graduate, founded the firm
- The technology focuses on dissolving patches for GLP-1 drug delivery
Innovative Drug Delivery Technology
The funding will support ArrayPatch’s development of its proprietary dissolving patch platform, which represents a potential alternative to injectable GLP-1 medications. GLP-1 receptor agonists have gained significant attention in recent years for their effectiveness in managing type 2 diabetes and obesity, though current formulations typically require injection administration.
ArrayPatch’s dissolving patch technology seeks to improve patient compliance and convenience by offering a non-invasive delivery method. The transdermal approach could reduce the barriers many patients face with injectable medications, potentially expanding access to these important therapeutic treatments.
Growing Irish Pharmaceutical Innovation Sector
The investment in ArrayPatch highlights Ireland’s expanding role in pharmaceutical innovation and technology development. The company’s emergence from University College Cork demonstrates the continued contribution of Irish research institutions to commercial biotechnology ventures.
Ireland’s pharmaceutical and biotechnology sector has attracted substantial investment in recent years, supported by organisations such as Enterprise Ireland, which provides funding and support to high-potential start-ups in the life sciences field. The country’s strong research base and established pharmaceutical manufacturing presence create an advantageous environment for companies developing novel drug delivery systems.
ArrayPatch joins a growing number of Irish companies working on advanced pharmaceutical technologies, contributing to the business ecosystem that has made Ireland a significant hub for global pharmaceutical operations and innovation.
Reporting based on original coverage by the original source.
